Hanna Dahlstrand

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Hanna Dahlstrand är docent i onkologi och ÖL i onkologi och gynonkologi
Karolinska Universitetssjh.
Hon är forskningsteamledare vid Onk-Pakt, KI, forskningsgruppen forskar på
gynekologisk cancer.

Artiklar

Article: CANCER CAUSES AND CONTROL. 2024;35(8):1101-1109
Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Skoeld C; Corvigno S; Dahlstrand H; Enblad G; Mezheyeuski A; Sundstroem-Poromaa I; Stalberg K; Tolf A; Glimelius I; Koliadi A
Article: THE LANCET. 2024;403(10421):31-43
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Oaknin A; Gladieff L; Martinez-Garcia J; Villacampa G; Takekuma M; De Giorgi U; Lindemann K; Woelber L; Colombo N; Duska L; Leary A; Godoy-Ortiz A; Nishio S; Angelergues A; Rubio MJ; Farinas-Madrid L; Yamaguchi S; Lorusso D; Ray-Coquard I; Manso L; Joly F; Alarcon J; Follana P; Romero I; Lebreton C; Perez-Fidalgo JA; Yunokawa M; Dahlstrand H; D'Hondt V; Randall L
Journal article: CANCER RESEARCH. 2023;83(8_Supplement):ct235
Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies
Hahn A; Irenaeus S; Wenthe J; Eriksson E; Schiza A; Dahlstrand H; Olsson-Strömberg U; Krause J; Sundin A; Sandin L; Jarblad JL; Liljefors MG; Rowinsky E; Loskog A; Ullenhag GJ
Article: SEMINARS IN CANCER BIOLOGY. 2022;86(Pt 3):207-223
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
Journal article: CANCER RESEARCH. 2021;81(22_Supplement):po-018-po-018
Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus
Wenthe J; Eriksson E; Sandin L; Lövgren T; Jarblad JL; Dahlstrand H; Olsson-Strömberg U; Schiza A; Sundin A; Irenaeus S; Rowinsky E; Ullenhag G; Loskog A
Article: EBIOMEDICINE. 2021;65:103269
The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types
Micke P; Strell C; Mattsson J; Martin-Bernabe A; Brunnstrom H; Huvila J; Sund M; Warnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicien G; Mollevi DG; Edqvist P-H; Reilly AO; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brandstedt J; Sartor H; Malmstrom P-U; Johansson M; Nodin B; Backman M; Lindskog C; Jirstrom K; Mezheyeuski A
Article: ADVANCES IN THERAPY. 2020;37(12):5023-5031
Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c⁺Expression in Tumor
Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
Article: GYNECOLOGIC ONCOLOGY. 2020;159(3):860-868
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
Corvigno S; Mezheyeuski A; De La Fuente LM; Westbom-Freme S; Carlson JW; Fernebro J; Avall-Lundqvist E; Kannisto P; Hedenfalk I; Malander S; Rolny C; Dahlstrand H; Ostman A
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2020;125(4):325-329
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Tholander B; Koliadi A; Botling J; Dahlstrand H; Von Heideman A; Ahlström H; Öberg K; Ullenhag GJ
Article: EMBO MOLECULAR MEDICINE. 2020;12(4):e11177
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer
Moyano-Galceran L; Pietila EA; Turunen SP; Corvigno S; Hjerpe E; Bulanova D; Joneborg U; Alkasalias T; Miki Y; Yashiro M; Chernenko A; Jukonen J; Singh M; Dahlstrand H; Carlson JW; Lehti K
Article: PLOS ONE. 2020;15(7):e0236291
Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers
Yang C; Zhang Y; Chen Y; Ragaller F; Liu M; Corvigno S; Dahlstrand H; Carlson J; Chen Z; Nasman A; Waraky A; Lin Y; Larsson O; Haglund F
Journal article: CLINICAL CANCER RESEARCH. 2019;25(22_Supplement):gmm-041-gmm-041
Abstract GMM-041: OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH
Moyano-Galceran L; Turunen SP; Pietilä E; Alkasalias T; Corvigno S; Hjerpe E; Joneborg U; Bulanova D; Eriksson M; Dahlstrand H; Carlson J; Lehti K
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2018;123(4):225-229
Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines-a survey in Sweden.
Halldorsdottir S; Dahlstrand H; Stålberg K
Article: NATURE BIOMEDICAL ENGINEERING. 2017;1(10):796-806
Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity
Tanaka N; Kanatani S; Tomer R; Sahlgren C; Kronqvist P; Kaczynska D; Louhivuori L; Kis L; Lindh C; Mitura P; Stepulak A; Corvigno S; Hartman J; Micke P; Mezheyeuski A; Strell C; Carlson JW; Moro CF; Dahlstrand H; Ostman A; Matsumoto K; Wiklund P; Oya M; Miyakawa A; Deisseroth K; Uhlen P
Article: THE JOURNAL OF PATHOLOGY: CLINICAL RESEARCH. 2017;3(3):214-224
Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker
Corvigno S; Frodin M; Wisman GBA; Nijman HW; Van der Zee AGJ; Jirstrom K; Nodin B; Hrynchyk I; Edler D; Ragnhammar P; Johansson M; Dahlstrand H; Mezheyeuski A; Ostman A
Article: ACTA ONCOLOGICA. 2016;55(12):1467-1476
Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO
Derogar M; Dahlstrand H; Carlsson S; Bjartell A; Hugosson J; Axen E; Johansson E; Lagerkvist M; Nyberg T; Stranne J; Thorsteinsdottir T; Wallerstedt A; Haglind E; Wiklund P; Steineck G
Article: LAKARTIDNINGEN. 2016;113:D4WM
[Difficult discussions with patients practiced at course with actors. A carefully planned strategy helps both physician and patient].
Danielsson A; Dahlstrand H; Edvinsson F; Tranberg M; Wrangsjö A; Fürst C-J
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY. 2016;35(3):256-263
A Cell Type Independent Binary Grading System Does Not Significantly Improve Endometrial Biopsy Interpretation
Nastic D; Kahlin F; Dahlstrand H; Carlson JW
Article: ONCOTARGET. 2016;7(14):18573-18584
Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival
Corvigno S; Wisman GBA; Mezheyeuski A; van der Zee AGJ; Nijman HW; Avall-Lundqvist E; Ostman A; Dahlstrand H
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2012;47(4):397-406
Risk factors and chemoprevention in Barrett's esophagus - an update
Winberg H; Lindblad M; Lagergren J; Dahlstrand H
Article: PLOS ONE. 2012;7(10):e46538
Prevalence of Human Papillomavirus (HPV) in Oesophageal Squamous Cell Carcinoma in Relation to Anatomical Site of the Tumour
Lofdahl HE; Du J; Nasman A; Andersson E; Rubio CA; Lu Y; Ramqvist T; Dalianis T; Lagergren J; Dahlstrand H
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;125(2):362-366
Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma?
Nasman A; Attner P; Hammarstedt L; Do J; Eriksson M; Giraud G; Ahrlund-Richter S; Marklund L; Romanitan M; Lindquist D; Ramqvist T; Lindholm J; Sparen P; Ye W; Dahistrand H; Munck-Wikland E; Dalianis T
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(20):3372-3379
Disclosure of incurable illness to spouses:: Do they want to know?: A Swedish population-based follow-up study
Dahlstrand H; Hauksdottir A; Valdimarsdottir U; Fuerst C-J; Bergmark K; Steineck G
Article: ANTICANCER RESEARCH. 2008;28(4B):2077-2080
Human papillomavirus frequency in oral and oropharyngeal cancer in greece
Romanitan M; Nasman A; Ramqvist T; Dahlstrand H; Polykretis L; Vogiatzis P; Vamvakas P; Tasopoulos G; Valavanis C; Arapantoni-Dadioti P; Banis K; Dalianis T
Article: MOLECULAR ONCOLOGY. 2007;1(3):350-355
Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7
Lindquist D; Romanitan M; Hammarstedt L; Naesman A; Dahistrand H; Lindholm J; Oneloev L; Ramqvist T; Ye W; Munck-Wikland E; Dalianis T
Article: ACTA OTO-LARYNGOLOGICA. 2007;127(9):988-992
The incidence of tonsillar cancer in Sweden is increasing
Hammarstedt L; Dahlstrand H; Lindquist D; (Dahlgren) LO; Ryott M; Luo J; Dalianis T; Ye W; Munck-Wikland E
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2007;133(9):673-678
Alcohol, smoking and human papillomavirus in laryngeal carcinoma:: a Nordic prospective multicenter study
Koskinen WJ; Brondbo K; Dahlstrand HM; Luostarinen T; Hakulinen T; Leivo I; Molijn A; Quint WG; Roysland T; Munck-Wikland E; Makitie AA; Pyykko I; Dillner J; Vaheri A; Aaltonen L-M
Article: INTERNATIONAL JOURNAL OF CANCER. 2006;119(11):2620-2623
Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer
Hammarstedt L; Lindquist D; Dahlstrand H; Romanitan M; Onelov (Dahlgren) L; Joneberg J; Creson N; Lindholm J; Ye W; Dalianis T; Munck-Wikland E
Article: ANTICANCER RESEARCH. 2006;26(3B):2205-2208
Molecular and virological studies on a rare case of biliary papillomatosis
Gunven P; Auer G; Gerdes U; Dahlstrand HM; Lewensohn-Fuchs I; Dalianis T
Article: ANTICANCER RESEARCH. 2005;25(6C):4375-4383
P16^INK4a correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma
Dahlstrand HM; Lindquist D; Björnestål L; Ohlsson A; Dalianis T; Munck-Wikland E; Elmberger G
Article: JOURNAL OF GENERAL VIROLOGY. 2005;86(Pt 6):1695-1702
Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment
Szeps M; Dahlgren L; Aaltonen LM; Öhd J; Kanter-Lewenshon L; Dahlstrand H; Munck-Wikland E; Grandér D; Dalianis T
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;112(6):1015-1019
Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients
Dahlgren L; Dahlstrand H; Lindquist D; Högmo A; Björnestål L; Lindholm J; Lundberg B; Dalianis T; Munck-Wikland E
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;107(2):244-249
Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors
Dahlgren L; Mellin H; Wangsa D; Heselmeyer-Haddad K; Björnestål L; Lindholm J; Munck-Wkland E; Auer G; Ried T; Dalianis T
Article: ANTICANCER RESEARCH. 2003;23(3C):2821-2828
Human papillomavirus and DNA ploidy in tonsillar cancer - Correlation to prognosis
Mellin H; Friesland S; Auer G; Dalianis T; Munck-Wikland E
Article: INTERNATIONAL JOURNAL OF CANCER. 2002;102(2):152-158
Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer
Mellin H; Dahlgren L; Munck-Wikland E; Lindholm J; Rabbani H; Kalantari M; Dalianis T
Article: ANTICANCER RESEARCH. 2001;21(1B):529-534
Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma - Relation to radiotherapy response and survival
Friesland S; Mellin H; Munck-Wikland E; Nilsson A; Lindholm J; Dalianis T; Lewensohn R
Article: INTERNATIONAL JOURNAL OF CANCER. 2000;89(3):300-304
Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival
Mellin H; Friesland S; Lewensohn R; Dalianis T; Munck-Wikland E
Article: IN VIVO. 1998;12(2):143-148
Adult X-linked immunodeficiency (XID) mice, IgM^-/- single knockout and IgM^-/-CD8⁺ double knockout mice do not clear polyomavirus infection
Berke Z; Mellin H; Heidari S; Wen T; Berglöf A; Klein G; Dalianis T
Visa fler

Alla övriga publikationer

Conference publication: 2022;:a411.1-a4a411
2022-RA-1007-ESGO High expression of FAP+ cancer-associated fibroblasts predict poor outcome in patients with high-grade serous ovarian cancer with high CD8-postive T-cell infiltration
Fernebro J; Corvigno S; Mezheieusky A; Karlsson JS; Fuente LMDL; Westbom-Fremer SM; Carlson J; Kannisto PM; Hedenfalk IM; Malander SM; Östman A; Dahlstrand H
Conference publication: 2020;:a70-a71
364 Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by brcawt status: prima/ENGOT-OV26/GOG-3012 study
Braicu EI; Pothuri B; Pérez-Fidalgo JA; O’malley D; Honhon B; Graybill W; Fabbro M; Dahlstrand H; Gupta D; Monk BJ
Conference publication: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2020;30(Suppl 4):a69-a70
347 Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial
Dahlstrand H; Pothuri B; Graybill W; de La Motte Rouge T; Mccormick C; Heitz F; Baurain J-F; Yong L; Monk BJ; González-Martin A
Preprint: SSRN ELECTRONIC JOURNAL. 2020
Stroma Amount in Human Cancer
Micke P; Strell C; Matttsson J; Brunnström H; Huvila J; Sund M; Wärnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicién G; Molleví DG; Edqvist P-H; O´Reilly A; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brändstedt J; Sartor H; Malmström P-U; Johansson M; Nodin B; Backman M; Lindskog C; Jirström K; Mezheyeuski A
Conference publication: CLINICAL CANCER RESEARCH. 2019;25(22):104
OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH
Moyano-Galceran L; Turunen SP; Pietila E; Alkasalias T; Corvigno S; Hjerpe E; Joneborg U; Bulanova D; Eriksson M; Dahlstrand H; Carlson J; Lehti K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e17526
The clinical outcome of FAP plus cancer-associated fibroblasts in high-grade serous ovarian cancer.
Dahlstrand H; Corvigno S; Mezheyeuski A; Carlson JW; Fernebro J; Holzlwimmer G
Corrigendum: NATURE BIOMEDICAL ENGINEERING. 2018;2(1):48
Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity (vol 1, pg 796, 2017)
Tanaka N; Kanatani S; Tomer R; Sahlgren C; Kronqvist P; Kaczynska D; Louhivuori L; Kis L; Lindh C; Mitura P; Stepulak A; Corvigno S; Hartman J; Micke P; Mezheyeuski A; Strell C; Carlson JW; Moro CF; Dahlstrand H; Ostman A; Matsumoto K; Wiklund P; Oya M; Miyakawa A; Deisseroth K; Uhlen P
Conference publication: CANCER RESEARCH. 2016;76:c38
Marker-defined perivascular cells predict prognosis and response to treatment
Corvigno S; Mezheyeuski A; Frodin M; Lindh MB; Guren TK; Pfeiffer P; Kure HE; Ikdahl T; Skovlund E; Tveit KM; Pietras K; Portyanko A; Hrynchyk I; Edler D; Dragomir A; Ponten F; Mulder J; Qvortrup C; Hallstrom M; Ohrling K; Wisman GBA; Avall-Lundqvist E; Johansson M; Harmenberg U; Nijman H; Sandstrom P; Dahlstrand H; Sorbye H; Ginnelius B; Van Der Zee A; Egevad L; Ostman A
Meeting abstract: CANCER RESEARCH. 2015;75:1537
Tumor stroma in serous ovarian cancer; inter and intra patient heterogeneity and impact on survival
Corvigno S; Wisman B; Van der Zee AGJ; Nijman HW; Mezheyeuski A; Lundkvist EA; Ostman A; Dahlstrand H
Book chapter: METHODS OF CANCER DIAGNOSIS, THERAPY, AND PROGNOSIS: METHODS OF CANCER DIAGNOSIS, THERAPY AND PROGNOSIS. 2010;p. 271-283
Role of Human Papillomavirus in Tonsillar Cancer
Munck-Wikland E; Hammarstedt L; Dahlstrand H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):6004
Human papillomavirus (HPV) as a risk factor for the increase in incidence of tonsillar cancer and its expression of E6 and E7
Dahlstrand H; Hammarstedt L; Lindquist D; Ye W; Dalianis T; Munck-Wikland E
Review: ANTICANCER RESEARCH. 2008;28(2B):1133-1138
Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer
Dahlstrand H; Nasman A; Romanitan M; Lindquist D; Ramqvist T; Dalianis T
Review: LAKARTIDNINGEN. 2006;103(44):3366-3368
[Human papillomavirus important factor in the increased incidence of tonsillar cancer].
Munck-Wikland E; Hammarstedt L; Lindquist D; Romanitan M; Dahlstrand H; Dalianis T
Review: LAKARTIDNINGEN. 2006;103(37):2650-2652
[Virus-like particles as cancer vaccine. Great expectations--not only for papillomavirus associated cancer].
Tegerstedt K; Andreasson K; Dahlstrand H; Ramqvist T; Dalianis T
Review: ADVANCES IN CANCER RESEARCH. 2005;93:59-89
Presence and influence of human papillomaviruses (HPV) in tonsillar cancer
Dahstrand HM; Dalianis T
Review: ANTICANCER RESEARCH. 2004;24(3B):1829-1835
Presence of human papillomavirus in tonsillar cancer is a favourable prognostic factor for clinical outcome
Dahlstrand H; Dahlgren L; Lindquist D; Munck-Wikland E; Dalianis T

Forskningsbidrag

The immune system and other cells surrounding the cancer cells in ovarian cancer - how do they affect prognosis and treatment results?
Swedish Cancer Society
1 January 2018
The immune system and other cells surrounding the cancer cells in ovarian cancer - how do they affect prognosis and treatment results?
Swedish Cancer Society
1 January 2017
Increasing the next of kin´s degree of preparedness for her or his spouse´s death due to cancer - a randomized intervention
Swedish Research Council
1 January 2015 - 31 December 2017

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2026

Examina och utbildning

Docent, onkologi, Karolinska Institutet, 2016
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2002
Läkarexamen, Karolinska Institutet, 1999

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI